---
title: "Aptevo Therap | 10-K: FY2025 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280683357.md"
datetime: "2026-03-26T20:18:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280683357.md)
  - [en](https://longbridge.com/en/news/280683357.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280683357.md)
generator: "portal-rs"
---

# Aptevo Therap | 10-K: FY2025 Revenue: USD 0

Revenue: As of FY2025, the actual value is USD 0.

EPS: As of FY2025, the actual value is USD -87.27.

EBIT: As of FY2025, the actual value is USD -26.31 M.

#### Net Loss

Aptevo Therapeutics Inc. reported a net loss of - $26.0 million in 2025, an increase from - $24.1 million in 2024.

#### Cash and Cash Equivalents

Cash and cash equivalents increased to $21.6 million as of December 31, 2025, compared to $8.7 million as of December 31, 2024.

#### Research and Development Expenses

Total research and development expenses were - $14.5 million in 2025, a slight increase from - $14.4 million in 2024.\- **Clinical Programs**: Expenses for Mipletamig increased to - $6.579 million in 2025 from - $3.835 million in 2024, while expenses for ALG.APV-527 decreased to - $0.477 million in 2025 from - $2.612 million in 2024.\- **Preclinical Program, General Research and Discovery**: Expenses decreased to - $7.484 million in 2025 from - $7.931 million in 2024.

#### General and Administrative Expenses

General and administrative expenses increased to - $11.8 million in 2025 from - $10.2 million in 2024.

#### Other Income, Net

Other income, net, was $0.3 million in 2025, down from $0.5 million in 2024.

#### Cash Flow from Operating Activities

Cash flow from operating activities was - $25.6 million in 2025, compared to - $23.8 million in 2024.

#### Cash Flow from Financing Activities

Cash flow from financing activities significantly increased to $38.5 million in 2025, primarily driven by $37.9 million net proceeds from common stock issuance and $0.6 million from common warrant exercise. In 2024, cash flow from financing activities was $15.6 million, mainly from $8.9 million net proceeds from common stock issuance and $6.7 million from common warrant exercise.

#### Liquidity and Capital Resources Outlook

Aptevo Therapeutics Inc. will require additional funding to support ongoing clinical development and commercial marketing due to expected significant operating losses. The company secured a $60.0 million Standby Equity Purchase Agreement in January 2026, bringing total SEPA capacity to $67.5 million, which, with current resources, is projected to support operations into 2029. However, substantial doubt exists about its ability to continue as a going concern without further financing or positive cash flow, though up to $5.8 million in milestone payments from Medexus may be received.

### Related Stocks

- [APVO.US](https://longbridge.com/en/quote/APVO.US.md)

## Related News & Research

- [Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML | APVO Stock News](https://longbridge.com/en/news/297911849.md)
- [Aptevo Therapeutics announces special shareholder meeting](https://longbridge.com/en/news/297564634.md)
- [Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results | APVO Stock News](https://longbridge.com/en/news/295932565.md)
- [Aptevo wins $1.5 million CARE Fund grant for APVO451 IND-enabling work](https://longbridge.com/en/news/295932679.md)
- [Aptevo targets solid tumors with planned Nectin-4 x PD-L1 dual-targeting platform strategy](https://longbridge.com/en/news/293969770.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**